Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time
The Oncologist · 06.12.2024 · 29 (12) · 1068-1078
DOI: 10.1093/oncolo/oyae282 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 29.10.2024. Verfasst von Luis E Raez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Program, Memorial Cancer Institute, Florida Atlantic University (FAU), Pembroke Pines, FL 33026, United States. Hauptthemen laut MEDLINE: Pyridines, Pyrazoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Selpercatinib is a selective RET inhibitor approved for treatment of RET-activated cancers. Adverse events (AEs) are manageable with dose modifications. This post hoc analysis characterized selpercatinib’s clinical safety profile after long-term follow-up in the safety population of LIBRETTO-001. Patients and Methods LIBRETTO-001 is an ongoing phase I/II, single-arm, open-label trial (NCT03157128). Eligible patients were ≥18 years old with diagnosis of advanced/metastatic RET fusion-positive solid tumor, RET-mutant medullary thyroid cancer, or other RET-activated tumors. In phase I, patients received selpercatinib 20 mg QD or 20-240 mg BID; patients in phase II received 160 mg BID. The analyzed population comprised all patients who received ≥1 selpercatinib dose and were followed up until data cutoff (January 13, 2023).
Results
For the 837 patients, median follow-up was 45.4 months (95% CI, 44.5-46.6); median time on treatment was 30.1 months (range 0.1-66.8). Grade ≥3 treatment-emergent AEs (TEAEs) were reported in 76.2% of patients; most common events were hypertension (19.7%), ALT increased (11.8%), and hyponatremia (9.2%). Serious TEAEs were reported in 51.4% of patients. Most frequently reported any-grade AEs at <6 months of treatment were fatigue (36.6%), dry mouth (32.8%), and ALT increased (30.5%); at ≥24 months of treatment, these were edema (63.2%), diarrhea (60.7%), and fatigue (53.0%). Selpercatinib-related TEAEs leading to reduced dosage were reported in 39.3%, those leading to treatment interruption were reported in 47.1%, and those leading to discontinuation were reported in 4.3% of patients.
Conclusion
Long-term treatment with selpercatinib is feasible. AEs are manageable with dose modifications, allowing most patients to continue safely on therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thoracic Oncology Program, Memorial Cancer Institute, Florida Atlantic University (FAU), Pembroke Pines, FL 33026, United States.
- Eli Lilly and Co., Indianapolis, IN, 46285, United States.
- Thoracic Oncology Program, Cleveland Clinic, Cleveland, OH, 44195, United States.
ORCID-Profile: Luis E Raez
Zitieren
APA
Raez, L. E., Massey, A. C., Barker, S. S., Peterson, P. M., Liming, K., & Pennell, N. A. (2024). Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. The Oncologist, 29(12), 1068-1078. https://doi.org/10.1093/oncolo/oyae282
Vancouver
Raez LE, Massey AC, Barker SS, Peterson PM, Liming K, Pennell NA. Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. The Oncologist. 2024;29(12):1068-1078. doi:10.1093/oncolo/oyae282
BibTeX
@article{Raez2024,
author = {Raez, Luis E and Massey, Ashish C and Barker, Scott S and Peterson, Patrick M and Liming, Katherine and Pennell, Nathan A},
title = {Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {12},
pages = {1068--1078},
doi = {10.1093/oncolo/oyae282}
}
EUVIMED